A Phase I Biological Study of Intraveous Azacitidine (Vidaza) in Hematologic Malignancies

Trial Profile

A Phase I Biological Study of Intraveous Azacitidine (Vidaza) in Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2009

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Sep 2009 Additional lead trial investigator (O'Connell C) added as reported by University of Southern California Norris Comprehensive Cancer Center record.
    • 15 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top